Fractured Spine Clinical Trials

Find Fractured Spine Clinical Trials Near You

A Prospective Multicenter Clinical Investigation Evaluating the Safety and Efficacy of the VCFix Spinal System in Stand-alone Configuration for Vertebral Augmentation (EXPAND)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is being conducted to evaluate the safety and performance of the VCFix Spinal System, a medical device designed to treat certain types of spinal fractures called vertebral compression fractures (VCFs) in adults. Up to 8 hospitals in Europe will take part in the study. All participants will receive treatment with the VCFix device. The treatment will be provided according to the intended use of the device and may be performed either with or without the use of a special bone cement. Participants will be assigned to one of two study groups before treatment: Cementless group: the VCFix device is implanted without bone cement. Cemented group: the VCFix device is implanted together with bone cement. The study will assess how well the treatment works and how safe it is. Researchers will evaluate: Changes in back pain 6 months after treatment compared with before treatment. Changes in daily functioning and ability to perform everyday activities 6 months after treatment compared with before treatment. Whether any serious device-related complications occur during the first month after treatment. The results will help determine whether treatment with the VCFix device provides benefits for patients with vertebral compression fractures while maintaining an acceptable safety profile.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 85
Healthy Volunteers: f
View:

• Subject is ≥ 21 to ≤ 85 years old.

• Single vertebral fracture which meets all of the following criteria:

‣ Type A fractures from AO spine classification (compression injuries);

⁃ Vertebral fracture located in the thoracic and lumbar regions of the spine

⁃ Fracture age \< 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)

⁃ Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence

⁃ Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery

• Subject has a NPRS back pain score of ≥5

• Subject is a candidate for surgical intervention based on investigator opinion

• Subject has a body Mass Index (BMI) \< 35

• Subject is mentally capable of complying with trial protocol requirements for the duration of the study

• Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent

Locations
Other Locations
France
Centre Hospitalier Métropole de Savoie
NOT_YET_RECRUITING
Chambéry
Germany
Wilhelmsburger Krankenhaus Groß-Sand
RECRUITING
Hamburg
Krankenhaus Mechernich
RECRUITING
Mechernich
Contact Information
Primary
Clinical Research Manager
expand@amberimplants.com
+31 15 200 2151
Time Frame
Start Date: 2025-11-04
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 148
Treatments
Experimental: Cemented cohort
Implant of the VCFix device with the use of PMMA bone cement
Experimental: Uncemented cohort
Implant of the VCFix device without the use of PMMA bone cement
Related Therapeutic Areas
Sponsors
Leads: Amber Implants B.V.

This content was sourced from clinicaltrials.gov